

**Feline Cancer Panel
Report**



VDI Lab Services
4685 Runway St. Ste K Simi Valley, CA 93063
ph: 805-577-6742 fax: 805-426-8115

PATIENT NAME: Willow Mareks
SPECIMEN ID: 479909
SPECIES: Feline
GENDER: Female Spayed
AGE: 5.0
WEIGHT: 7.7 lb
BREED: DSH

MRN: 1102368
DRAW DATE: 7-Mar-23
RECEIVED DATE: 10-Mar-23
REPORT DATE: 10-Mar-23
SAMPLE TYPE: Dried Serum - 2
PATIENT STAGE:

VETERINARIAN:
FACILITY:

Relevant Context (provided on TRF)

<input type="checkbox"/> Corticosteroids	<input type="checkbox"/> Antibiotics	<input type="checkbox"/> Suspected Mass	<input type="checkbox"/> Hypercalcemia
<input type="checkbox"/> NSAIDs	<input type="checkbox"/> Anemia	<input type="checkbox"/> Enlarged Node	<input type="checkbox"/> B12 Deficiency
<input type="checkbox"/> Chemotherapy	<input type="checkbox"/> GI Signs	<input type="checkbox"/> Fever	<input type="checkbox"/> Known Disease

Neoplasia Index

High Positive

9.9

Index

Negative: <5.3
Equivocal: 5.3
Positive: 5.4 - 8.9
High Positive: ≥ 9.0

TK1

Highly Elevated

27.2

U/L

Normal: ≤ 3.0
Equivocal: ≤ 5.5
High (H): 5.5 - 24.9
Highly Elevated (HE): ≥ 25

fHPT

High

270.1

mg/dL

Decreased (D): < 25
Normal: 25 - 64.9
Mild Inflamm (m): 65 - 140
Mod Inflamm (M): 140-225
High Inflamm (H): ≥ 225.1

Interpretive Comments

The Neoplasia Index is high positive because there sufficient elevation in TK1 and HPT for a high risk of neoplasia. Careful patient examination should be performed. If a mass has been identified, there is a high probability the mass is malignant.

Interpretive Comments

Highly elevated levels of TK1 (>25 U/L) most commonly occurs in lymphoma and high grade tumors.

Interpretive Comments

HPT is highly elevated. Infection, which can be primary or secondary to cancer, should be ruled-out. The use of corticosteroids, NSAIDS, or other anti-inflammatory agents can suppress HPT. Recommend careful patient evaluation.

CAR: N/A



Comment: CAR not available for felines

Normal Range <1.6

Contextual Comments (if needed) - need consult? email consult@vdlab.com

code 343

**Other Conditions
to rule-out**

IMHA, ITP

Patient Monitoring Provides Guidance

Thymidine Kinase, type 1 (TK1) is a DNA proliferation enzyme and is elevated in dividing cancer cells. During therapy (chemo/surgery) the source of TK1 is reduced/eliminated and serum TK1 (sTK1) levels will fall. Conversely, growing cancer cells during disease recurrence will increase sTK1 levels. Suspected undiagnosed patients can also be followed in the same manner. This makes the Cancer Panel an effective tool for patient monitoring. **Need Consultation? email consult@vdilab.com**

RETEST WINDOW

Depending upon the type of cancer different monitoring intervals are recommended (see below). Use the chart below to identify appropriate retest window for this patient. These windows may be adjusted by the presence of clinical signs or elevated CAR (CRP/Albumin Ratio). Repeat tests within 6 months of previous automatically receive a discounted rate.




Monitoring Purpose	Retest Window	Notes
Developing Disease, but unconfirmed		Retest window is recommended based on common applications absent any context. For more case-specific guidelines, email: consult@vdilab.com
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Therapeutic Monitoring		
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Remission Monitoring		
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Mass Removal/Metastatic Disease	Apr 04 - Apr 18	

INTERPRET THE REPORT

VDI Cancer Panel monitoring reports come with a number of important indicators. Use the key below to interpret what the results mean in context with your patient.




Significant Change

a change of 40% or more from prior. Studies show this level of change can precede cancer recurrence.

Indicator	What does it signify?	What does it mean?
	Significant reduction or improvement of at least 40% over previous	Indicates therapy is effective in reducing or eliminating the tumor or inflammation
 TK1 Only	Significant increase in TK1 however TK1 remains below the 9U/L threshold	Indicates the level of change is worth watching – changes in clinical status of the patient is important
	Significant increase in the biomarker above critical thresholds	Studies show this level of change in TK1 often precedes cancer recurrence, or is consistent with malignant tumor growth.

Trending

2 or more data points in the same direction. Short-term trending events are the most valuable in confirming cancer recurrence.

Indicator	What does it signify?	What does it mean?
	Significant trend of 2 or more data points in the reduction or improvement of biomarker	Downward trending provides confirmation of effective therapy
	2 data points in the same direction of high biomarker levels	Upward trending has high probability of disease recurrence (TK1) or growing inflammation (CRP/HPT) and requires immediate intervention with either a change in therapy or rescue therapy
	3 data points in the same direction of high biomarker levels	